Literature DB >> 9247479

Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis.

L Ruiz-del-Arbol1, A Monescillo, W Jimenéz, A Garcia-Plaza, V Arroyo, J Rodés.   

Abstract

BACKGROUND & AIMS: Therapeutic paracentesis may be associated with a circulatory dysfunction, manifested by a marked increase of the plasma renin activity and plasma norepinephrine. The aim of the study was to characterize the systemic and hepatic hemodynamic changes associated with paracentesis-induced circulatory dysfunction.
METHODS: Changes in plasma renin, aldosterone, and norepinephrine, and in systemic and hepatic hemodynamics were assessed 1 hour and 6 days after complete mobilization of ascites in 37 patients treated by total paracentesis plus intravenous dextran-70 infusion.
RESULTS: Paracentesis-induced circulatory dysfunction occurred in 10 patients (renin and norepinephrine increased from 9.0 +/- 10.5 to 28.8 +/- 19.0 ng.mL-1.h-1 and from 752.0 +/- 364.0 to 1223.0 +/- 294.0 pg/mL, respectively) and was associated with significant reduction in systemic vascular resistance (-13.0% +/- 2.6%; P < 0.05) and increase in hepatic venous pressure gradient (from 19.5 +/- 1.5 to 22.5 +/- 2.4 mm Hg; P < 0.01). In the remaining 27 patients, mobilization of ascites also induced a significant but smaller reduction in systemic vascular resistance (-5.0% +/- 1.6%; P < 0.05) without significant changes in renin, norepinephrine, and hepatic venous pressure gradient.
CONCLUSIONS: Paracentesis-induced circulatory dysfunction is predominantly caused by an accentuation of the arteriolar vasodilation already present in untreated cirrhotic patients with ascites. The homeostatic activation of endogenous vasoactive systems may account for the increased intrahepatic vascular resistance associated with this condition.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9247479     DOI: 10.1053/gast.1997.v113.pm9247479

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  57 in total

1.  Predictors of large volume paracantesis induced circulatory dysfunction in patients with massive hepatic ascites.

Authors:  G Nasr; A Hassan; S Ahmed; A Serwah
Journal:  J Cardiovasc Dis Res       Date:  2010-07

Review 2.  Clinical use of albumin.

Authors:  Paolo Caraceni; Manuel Tufoni; Maria Elena Bonavita
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

Review 3.  Hepato-cardiac disorders.

Authors:  Yasser Mahrous Fouad; Reem Yehia
Journal:  World J Hepatol       Date:  2014-01-27

Review 4.  Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease.

Authors:  S Møller; J H Henriksen
Journal:  Heart       Date:  2002-01       Impact factor: 5.994

Review 5.  Clinical use of albumin in hepatology.

Authors:  Matteo Garcovich; Maria Assunta Zocco; Antonio Gasbarrini
Journal:  Blood Transfus       Date:  2009-10       Impact factor: 3.443

6.  Transjugular intrahepatic portosystemic shunt in the management of refractory ascites.

Authors:  Guadalupe Garcia-Tsao
Journal:  Semin Intervent Radiol       Date:  2005-12       Impact factor: 1.513

Review 7.  Acute kidney injury in patients with cirrhosis: perils and promise.

Authors:  Justin M Belcher; Chirag R Parikh; Guadalupe Garcia-Tsao
Journal:  Clin Gastroenterol Hepatol       Date:  2013-04-10       Impact factor: 11.382

8.  The combination of octreotide and midodrine is not superior to albumin in preventing recurrence of ascites after large-volume paracentesis.

Authors:  Khurram Bari; Cecilia Miñano; Martha Shea; Irteza B Inayat; Hashem J Hashem; Hochong Gilles; Douglas Heuman; Guadalupe Garcia-Tsao
Journal:  Clin Gastroenterol Hepatol       Date:  2012-07-16       Impact factor: 11.382

Review 9.  Pathophysiology and management of pediatric ascites.

Authors:  Mahmoud Sabri; Miguel Saps; John M Peters
Journal:  Curr Gastroenterol Rep       Date:  2003-06

10.  Cirrhotic ascites review: Pathophysiology, diagnosis and management.

Authors:  Christopher M Moore; David H Van Thiel
Journal:  World J Hepatol       Date:  2013-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.